The Mainz company has made its first strategic decision following the founders departure and will stick with mRNA technology.
Following the departure of its founders BioNTech has taken a key strategic step. The company will continue to focus on mRNA the technology that made it globally known through its corona vaccine. Several people familiar with the matter confirmed the decision. Hundreds of employees are expected to move to a new company linked to the founders. Details on which research areas stay with BioNTech and which transfer to the founders form part of the separation plan. The report originates from Munich and is based on information available to Handelsblatt.
